Research programme: aurora kinase inhibitors - AstraZeneca

Drug Profile

Research programme: aurora kinase inhibitors - AstraZeneca

Alternative Names: Compound 677; ZM 447439

Latest Information Update: 22 Jan 2008

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Quinazolines
  • Mechanism of Action Aurora kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Haematological malignancies

Most Recent Events

  • 16 Jan 2006 Preclinical trials in Haematological malignancies in United Kingdom (unspecified route)
  • 16 Jan 2006 Data presented at the 47th Annual Meeting and Exposition of the American Society of Hematology (ASH-2005) have been added to the Cancer pharmacodynamics section
  • 07 Jul 2004 Data presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO-2004) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top